company background image
B8FK logo

Biofrontera XTRA:B8FK Stock Report

Last Price

€2.61

Market Cap

€15.9m

7D

-12.7%

1Y

-86.0%

Updated

16 Jul, 2024

Data

Company Financials

B8FK Stock Overview

A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.

B8FK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Biofrontera AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biofrontera
Historical stock prices
Current Share Price€2.61
52 Week High€18.90
52 Week Low€2.35
Beta0.53
11 Month Change-11.97%
3 Month Change-64.49%
1 Year Change-85.97%
33 Year Change-95.46%
5 Year Change-98.27%
Change since IPO-99.19%

Recent News & Updates

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

May 21
Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

Recent updates

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

May 21
Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07
Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07
Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08
Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14
Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholder Returns

B8FKDE PharmaceuticalsDE Market
7D-12.7%0.6%0.6%
1Y-86.0%-19.3%3.4%

Return vs Industry: B8FK underperformed the German Pharmaceuticals industry which returned -19.3% over the past year.

Return vs Market: B8FK underperformed the German Market which returned 3.4% over the past year.

Price Volatility

Is B8FK's price volatile compared to industry and market?
B8FK volatility
B8FK Average Weekly Movement14.5%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement4.7%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.5%

Stable Share Price: B8FK's share price has been volatile over the past 3 months.

Volatility Over Time: B8FK's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199797n/awww.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin.

Biofrontera AG Fundamentals Summary

How do Biofrontera's earnings and revenue compare to its market cap?
B8FK fundamental statistics
Market cap€15.86m
Earnings (TTM)€398.00k
Revenue (TTM)€30.16m

39.9x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B8FK income statement (TTM)
Revenue€30.16m
Cost of Revenue€6.22m
Gross Profit€23.94m
Other Expenses€23.55m
Earnings€398.00k

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.065
Gross Margin79.38%
Net Profit Margin1.32%
Debt/Equity Ratio2.7%

How did B8FK perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.